FBXO9 and cancer: Silencing FBXO9 in A549 cancer cells by siRNA transfection substantially increased the expression of active β-catenin (the primary effector of the canonical Wnt signaling pathway), C-Myc and cyclin D1 (both important downstream targets of this pathway) upon FBXO9 depletion (Fig. 7A).